| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Aim：The purpose of this study was to investigate effects of M-CSF receptor antagonist on HCC. Materials and Method：C57/BL6 mice were treated with diethyl nitrosamine (DEN) intraperitoneally. For treatment group, M-CSF receptor antagonist (GW2580) was treated every day. Incidence of tumors was assessed after treatment. Mouse HCC cells (MH134) were implanted to same strain C3H mice by subcutaneous injection (1 ×105/animal). Tumor progression was assessed after 3 weeks.In the nude mouse, human HCC cells (HuH7) were implanted by intra-splenic injection. Tumor progression in the spleen was assessed after 3 weeks.Result：Hepatic tumors diagnosed as hepatocellular adenoma or HCC were observed in animals treated with DEN. In contrast, tumor incidence was significantly reduced in DEN-treated animals with GW2580. Growth of implanted both of HCC was significantly inhibited by GW2580 in vivo. Conclusions：M-CSF and/or its receptor could be a new therapeutic target for HCC.
|
